Putnam Associates Case Interview 2026: The Firm Behind It

Why Putnam Associates is no longer the name on the door

The Our teams page states the change in its own words. It says the group is "evolving from Inizio Advisory to Inizio Ignite," and lists the businesses it brings together: Putnam, Research Partnership, STEM, and Vynamic. Putnam is the strategy consulting team of the four. The page says that team "bridges science and strategy to enable confident decision-making and build value for pharma."

Two names are therefore in play at once, and both are correct.

That last row is the one that costs candidates time. Search the old name and you get pages built on a site that no longer serves content. Some of it describes a firm that was independent, then part of Inizio Advisory, and is now part of Inizio Ignite. Ownership changed twice in a few years. Any description of a process written before those moves is a guess about today.

The firm also names its own reporting line. The same page introduces "Matt Riordan, Group President, Putnam." If you want to know who runs the practice you are applying to, that is the published answer, and it is one of very few published answers about Putnam that exist.

What the campus posting commits to, starting at a 3.3 GPA

The live Associate Consultant campus posting is the single most useful document the firm puts out. It is a job advert, so treat it as one. But it carries numbers, and numbers are checkable.

Read the team size line twice. Four to seven people, led by a Partner, is a short chain. On a larger firm's team you may sit two or three levels below the person who talks to the client. Here you do not. That is the honest version of the boutique pitch, and it tells you what the interview is screening for: someone who can build a model and then say what it means out loud.

The grade floor is unusual to see written down. Across the campus postings we read this season, it is the only numeric GPA condition we found. It means a candidate below 3.3 knows the answer before applying, and a candidate at 3.4 knows the bar is met while the preference sits higher.

The summer program posting is stricter still. It runs ten weeks, it is for current juniors graduating in June 2028, and it says that "MBA students, current seniors, and individuals who have already graduated are not eligible." That version is based in London. High performers "may be considered for full-time return offers."

One more line, and it saves people a wasted application. Every posting carries the note that Putnam Associates "is in no way affiliated with Putnam Investments and that this is not a finance opportunity."

The mechanics in writing: Greenhouse, and a camera on

Here is the whole of it, and it is short.

The group's applying for a role page exists to warn about recruitment fraud. That purpose is why it is specific. To tell you what a fake looks like, it has to tell you what the real thing looks like.

It says recruiters "will always interview you face to face or via phone or video conference (with our camera on)." It says the group "never uses Skype, Telegram, WhatsApp, Google Hangouts, text, live chat or email to conduct interviews." It adds that a recruiter may first reach you on LinkedIn, but will never cold call you or email you out of the blue.

The archived Putnam version of that page, read in a snapshot dated 8 October 2025, went one step further. It said every applicant is "re-routed to Greenhouse to submit a formal application," and that if you did not apply through Greenhouse, "the role is likely fake." It also said all interviews are scheduled by the talent team.

Now see what that does and does not give you. It gives you a channel and a modality. Your application is on Greenhouse, a coordinator books your slots, and you will be on video or in a room with the camera on at their end. It gives you nothing about the number of conversations, their order, their length, or whether a case appears in the first one or the third.

That silence is the real finding of this page. The firm names a GPA floor to three significant figures and never names a round count. Treat the invitation email as the only schedule that exists, and read it closely, because nothing on the public web substitutes for it.

The market a Putnam Associates case sits in has price cliffs

Putnam names its own subjects. The team page lists therapeutic area strategy, data and AI strategy, go to market strategy, commercialization and growth, evidence generation, and value, pricing and access. The experienced hire postings describe that last practice as work on "pricing, market access, value strategy, launch planning, payer strategy, and commercialization."

You cannot learn a case from that list. You can learn the arithmetic that any of those cases will rest on, and that arithmetic is published by regulators rather than by consultancies.

Two mechanics are worth knowing cold before any US pharma case.

Negotiated Medicare prices now have dates. The CMS page on selected drugs and negotiated prices states that maximum fair prices for the second cycle, covering fifteen Part D drugs, "will go into effect on January 1, 2027." It states that all fifteen manufacturers in the third cycle agreed to take part, that those talks run through 2026, and that the resulting prices "become effective beginning in 2028." A brand's revenue line therefore carries a dated cliff you can name in the first minute of a case.

Competitive entry ends the negotiation. The same page says a drug stops being a selected drug once FDA has approved a generic or licensed a biosimilar, and that product "is marketed pursuant to such approval or licensure." Approval alone is not enough. Launch is.

The benefit itself keeps moving too. CMS reissues the rules of the Part D benefit every year, through what it calls the Part D Redesign Program Instructions, with a final set published for calendar year 2026.

That is why the FDA biosimilar list is a useful thing to have seen. It carries each approved biosimilar, its approval month, and the reference product it copies. In 2026 alone it records approvals referencing Rituxan, Lantus, Lucentis, Neulasta, Simponi and Novolog. If a case mentions an entrant, this is where you check whether one exists.

A worked case: the price cliff on a Part D brand

The numbers below are invented. The mechanics are the ones above. Read it as a rehearsal of the arithmetic. Putnam publishes no case of its own.

Your client sells an oral therapy in the United States. Net revenue is $1.2 billion a year, from 100,000 patients at $12,000 each. Sixty percent of those patients are covered by Medicare Part D. The drug has been selected for negotiation. The negotiated price lands 40% below today's net price. What happens, and what do you do about it?

1. Split the base before touching the price. Part D is 60,000 patients and $720 million. The commercial book is 40,000 patients and $480 million. Only the first half is repriced.
2. Run the repricing. The new Part D net price is $12,000 less 40%, so $7,200. At unchanged volume that is 60,000 times $7,200, or $432 million. The brand loses $288 million a year on the same patients.
3. Ask the question that changes the answer. Does a lower price bring more patients? Lower patient cost sharing can lift starts and refills. Say volume rises 10%. Then 66,000 patients times $7,200 is $475 million, and the loss narrows to $245 million. Volume recovers about 15% of the hit, and no more.
4. Sanity check the scale. A $245 million loss against $1.2 billion is roughly a fifth of US revenue, arriving on one dated day. That makes it a portfolio problem, and saying so out loud is the move.
5. Recommend, first sentence. "Plan for a $245 million annual gap from the effective date, and fund it from the label rather than the price. A second indication costing $150 million that adds 12,000 patients at $7,200 brings $86 million of net revenue a year, so it clears its own cost in under two years on revenue, and I would redo that on contribution before committing. The risk is timing: the indication must land before the cliff, or it funds nothing."

Notice what carried the case. Splitting the base came before any percentage. The volume question was asked out loud before any number moved. The payback line divided $150 million by $86.4 million, said one and seven tenths of a year, and named the fact that $86 million is revenue rather than margin.

Where a pricing answer loses its points

Putnam publishes no marking scheme. The hundred points below are ours, written by us: the dimensions our own grader measures on a numerical answer. Putnam has never seen them, and no firm in this industry publishes a rubric of its own.

What Putnam does not publish, and what to do instead

No round count, and no order. The team page is silent, the group careers page is silent, and so is every posting we read. Any number you find elsewhere came from somewhere other than the firm.

No case format. Whether the case is led by the interviewer, handed to you in writing, or presented back is not stated anywhere.

No sample case. Nothing on any Putnam or Inizio page works an example through, which is why the case above is ours and is labeled as ours.

No online assessment, named or denied. Silence is not a promise that none exists. Your invitation will say.

No scoring, no threshold, no compensation figure. The campus posting offers a "market-leading base salary" and an annual bonus, with no number attached.

No first hand accounts we will cite. Candidate reports about Putnam do exist online. They sit on forums, on review aggregators and on preparation sites, and we do not treat any of those as sources. So this page describes what the firm states and stops there.

So prepare against the two things that are knowable. The first is the seat, and what a four to seven person team asks of the person at the bottom of it: a model that holds, and a sentence that says what it means. Putnam names that seat Associate Consultant and publishes nothing further about it. The second is the subject matter, because Putnam only does one industry. Work pharma cases and market sizing until the denominator stops being the thing you get wrong, and use practice for timed repetitions.

If your invitation contradicts anything here, the invitation wins. Send us what it said and the date it arrived, and we will read it against the firm's own pages before changing a word.

What changed on the Putnam page

We correct in public and we put a date on it. The body above says what the firm publishes today; this log says what this page used to say.

29 September 2026. Two claims are gone because neither came from the firm. The page told you what Putnam cases contain, and it told you which candidates do well in them. Putnam publishes nothing at all about its interviews, so both sentences were removed rather than rewritten. The page now stops where the published record stops.

29 September 2026. The firm name was updated throughout. The old domain, putassoc.com, answers with a redirect to Inizio, and the published brand is Putnam inside Inizio Ignite. An earlier version used Putnam Associates as if it were still the operating name, which sent readers to a site that no longer serves content.

29 September 2026. The Part D case was recalculated by hand, line by line, and it holds: $720 million repriced at $7,200 gives $432 million, a $288 million gap, narrowed to $245 million when volume rises a tenth, which recovers 15% of the hit. One thing was understated. The payback line treats $86 million as if it were margin, and it is net revenue, so the page now says so and asks you to redo it on contribution before recommending anything.

29 September 2026. The claim that most firms never publish a GPA floor was replaced by what we can actually stand behind, which is the set of campus postings we read this season.